European equities traded in the US as American depositary receipts were edging lower Tuesday morning, declining 0.14% to 1,308.28 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biotech firm BioNTech (BNTX) and internet advertising company Criteo (CRTO), which rose 5% and 4.6% respectively. They were followed by medical device maker EDAP TMS (EDAP) and biopharmaceutical company DBV Technologies (DBVT), which were up 3.4% each.
The decliners from continental Europe were led by furniture maker Natuzzi (NTZ) and biopharmaceutical company Grifols (GRFS), which fell 8.1% and 7.1% respectively. They were followed by semiconductor company Sequans Communications (SQNS) and financial services company Banco Santander (SAN), which lost 3.1% and 2% respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical companies Verona Pharma (VRNA) and Adaptimmune Therapeutics (ADAP), which climbed 7.6% and 5.4% higher respectively. They were followed by biopharmaceutical company Amarin (AMRN) and utility company National Grid (NGG), which increased 3.2% and 0.9% respectively.
The decliners from the UK and Ireland were led by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company Akari Therapeutics (AKTX), which tumbled 29.9% and 25.5% respectively. They were followed by insurance firm Prudential (PUK) and biopharmaceutical company Mereo BioPharma Group (MREO), which dropped 2.7% and 0.6% respectively.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。